LifeMD achieved record quarterly revenue and adjusted EBITDA in Q4 2024, with consolidated revenue increasing 43% year-over-year to $64.3 million and adjusted EBITDA increasing 78% to $9.0 million. The telehealth segment was a key driver, with revenue up 60% and adjusted EBITDA up 396%.
Consolidated revenues increased 43% year-over-year to $64.3 million, with telehealth revenue up 60%.
Adjusted EBITDA increased 78% to $9.0 million, and telehealth adjusted EBITDA increased 396% to $5.9 million.
Full-year cash flow from operations increased 99% to $17.5 million, generating positive full-year net cash flow.
The company exited 2024 with over $35 million in cash and introduced strong 2025 guidance for revenue and adjusted EBITDA.
LifeMD provided strong guidance for both Q1 2025 and the full year 2025, anticipating continued growth in revenue and adjusted EBITDA, particularly within its telehealth segment.